| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10968194 | Vaccine | 2011 | 11 Pages |
Abstract
⺠We model cost-effectiveness of the three conjugate pneumococcal vaccines in Norway. ⺠We estimate costs and epidemiological burden of pneumococcal and NTHi. ⺠PHiD-CV and PCV13 give similar protection against deaths, IPD, sequelae and pneumonia. ⺠PHiD-CV addresses AOM and myringotomy more effectively than PCV13. ⺠PHiD-CV saves more treatment and indirect costs and is more cost-effective.
Keywords
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Bjarne Robberstad, Carl R. Frostad, Per E. Akselsen, Kari J. Kværner, Aud K.H. Berstad,